Current Landscape of Life Sciences The life sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices ...

Rare diseases, defined in the U.S. as conditions affecting fewer than 200,000 people, can take years, if not decades, to ...

MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on ...

A team of cancer genomics scientists from The University of Manchester and The Institute of Cancer Research, London, ...

Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have ...

Immune checkpoint inhibitors have transformed cancer care, yet only a minority of patients respond to monotherapy, and immune-related adverse events remain a major concern.

Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized as a precursor state that predisposes individuals to myeloid malignancies ...